Classifying a cancer disease using CAIX expression

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 10620208
APP PUB NO 20160002350A1
SERIAL NO

14769541

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention relates to a carbonic anhydrase IX targeting compound for the use in the treatment of cancer, wherein the use comprises quantifying CAIX expression as well as the determination of a CAIX score based on the CAIX expression. The present invention relates further to a method for diagnosing, predicting and/or classifying a cancer disease comprising quantifying CAIX expression, and the determination of a CAIX score.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
WILEX AG81675 MÜNCHEN

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Bevan, Paul Henley-on-Thames, GB 1 0
Fall, Barbara Anzing, DE 1 0
Klöpfer, Pia Munich, DE 1 0
Wilhelm, Olaf Munich, DE 15 90

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Oct 14, 2027
11.5 Year Payment $7400.00 $3700.00 $1850.00 Oct 14, 2031
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00